News | News By Subject | News by Disease News By Date | Search News

Hemophilia B News Articles

Get Our FREE
Industry eNewsletter
email:    
Top Breaking News
Cambridge's Dimension Therapeutics (DMTX) Tanks to a New Low After Revealing Interim Hemophilia B Data     2/1/2017
SoCal's Arrowhead Pharma (ARWR) Stock Craters After Terminating 30% of Workforce, Discontinuing Work on Lead Hep B Drugs     12/1/2016
Shire (SHPG) Kills Baxalta (BXLT)'s Hemophilia B Program; Clears Path for BioMarin (BMRN), Spark Therapeutics (ONCE) and uniQure (QURE)     8/4/2016
FDA Calls Pfizer (PFE), Spark Therapeutics (ONCE)'s Hemophilia B Drug a Breakthrough     7/22/2016
Sources Reveal Biogen (BIIB) is Exploring Sale of Hemophilia Assets     4/12/2016
Pfizer (PFE)'s Hemophilia B Drug Cuts Bleeding in Late-Stage Study     3/9/2016
FDA Green Lights CSL Behring's Idelvion for Hemophilia B     3/7/2016
Biogen Idec (BIIB) Will Be Hiring in R&D After Around 20 Employees Leave Following Review     3/17/2015
AmerisourceBergen Corporation (ABC) the “Pony to Ride” for Biosimilar Opportunities, Says UBS     3/16/2015
Spark Therapeutics Strikes $280 Million Hemophilia B Pact With Pfizer (PFE)     12/9/2014
Analyst: Current Crop of Biotech IPOs a Mixed Bag of Low Market Caps, Little Data     12/3/2014
Best Value In Biotech? Actavis (ACT), Says UBS     11/17/2014
Baxter International, Inc. (BAX) Opens Its First State-Of-The-Art Biologics Facility In Asia     8/11/2014
Pfizer Inc. (PFE) Hemophilia B Treatment Regimen Meets Endpoint In Phase 3 Trial     7/16/2014
FDA Approves Biogen Idec, Inc. (Massachusetts) (BIIB)'s Hemophilia B Drug Alprolix     3/31/2014

News from Around the Web

Press Releases
Catalyst Biosciences Announces Positive Factor IX Clinical Data     9/6/2017
uniQure (QURE) Announces The Successful Development And Scale-Up Of Manufacturing Processes For Its Hemophilia B Gene Therapy Program     7/21/2017
uniQure (QURE) Presents New Clinical Data In Hemophilia B Patients Demonstrating Therapeutic Efficacy Of AAV5 Gene Therapy In The Presence Of Pre-Existing Neutralizing Antibodies     7/11/2017
Catalyst Biosciences’ Factor IX Granted Orphan Drug Designation In Europe     6/28/2017
Catalyst Biosciences Announces Achievement Of Stable Normal Factor IX Blood Levels In A Preclinical Subcutaneous Dosing Model     6/26/2017
Catalyst Biosciences And ISU Abxis Complete Dosing Of First Patient Cohort In Hemophilia B Clinical Trial     6/14/2017
Catalyst Biosciences Announces Presentations On Its Next-Generation Subcutaneous Hemophilia Product Candidates At The 2017 International Society On Thrombosis And Haemostasis (ISTH) Meeting     6/8/2017
Catalyst Biosciences’ Factor IX Recommended For Orphan Drug Designation In Europe     5/31/2017
Dimension Therapeutics (DMTX) Throws In The Towel On Hemophilia B Drug     5/10/2017
uniQure (QURE) Receives EMA Priority Medicines (PRIME) Designation For AMT-060 In Hemophilia B     4/25/2017
uniQure (QURE) Announces It Will Not Seek Marketing Authorization Renewal For Glybera In Europe     4/20/2017
Key Milestone Reached In Catalyst Biosciences’s Subcutaneous Factor IX Program     4/11/2017
Aptevo Therapeutics (APVO) Presents New Clinical Data Evaluating The Safety And Efficacy Of IXINITY In Children With Hemophilia B     4/10/2017
Bioverativ (BIVVV) Release: Long-term Safety And Efficacy Extension Study Data Of ALPROLIX For Hemophilia B Published In Thrombosis And Hemostasis     3/2/2017
uniQure (QURE) Announces FDA Breakthrough Therapy Designation For AMT-060 In Hemophilia B     1/30/2017

//-->